Treatment-Free Remission After Second-Line Nilotinib Treatment
Authors: Arpana Bansal, Sarah Jaroudi, Meredith Gavin, Alan N. Peiris
Journal: Annals of Internal Medicine (2018)

Letters2 October 2018Treatment-Free Remission After Second-Line Nilotinib TreatmentArpana Bansal, MS, Sarah Jaroudi, BS, Meredith Gavin, BS, and Alan N. Peiris, MD, PhDArpana Bansal, MSTexas Tech University Health Sciences Center, Lubbock, Texas (A.B., S.J., M.G., A.N.P.)Search for more papers by this author, Sarah Jaroudi, BSTexas Tech University Health Sciences Center, Lubbock, Texas (A.B., S.J., M.G., A.N.P.)Search for more papers by this author, Meredith Gavin, BSTexas Tech University Health Sciences Center, Lubbock, Texas (A.B., S.J., M.G., A.N.P.)Search for more papers by this author, and Alan N. Peiris, MD, PhDTexas Tech University Health Sciences Center, Lubbock, Texas (A.B., S.J., M.G., A.N.P.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L18-0430 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Mahon and colleagues (1) report that nilotinib may help patients with chronic myeloid leukemia (CML) achieve treatment-free remission. We commend the inclusiveness of their multicenter, international study of 163 patients. At least 10% of these patients had biochemical abnormalities. The absence of information on the results of thyroid function tests in these patients is therefore an important omission.Tyrosine kinase inhibitors (TKIs), including second-generation agents, are known to affect thyroid function in patients with CML (2). Kim and associates (2) noted thyroid abnormalities in approximately 55% of patients with CML treated with nilotinib. Thyroid dysfunction—especially hypothyroidism diagnosed ...References1. Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168:461-70. [PMID: 29459949]. doi:10.7326/M17-1094 LinkGoogle Scholar2. Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plöckinger U, et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 2010;20:1209-14. [PMID: 20929406] doi:10.1089/thy.2010.0251 CrossrefMedlineGoogle Scholar3. Sakurai K, Fukazawa H, Arihara Z, Yoshida K. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med. 2010;222:39-44. [PMID: 20814176] CrossrefMedlineGoogle Scholar4. Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, et al. Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced nonthyroidal cancer patients. Thyroid. 2018;28:437-44. [PMID: 29652599] doi:10.1089/thy.2017.0579 CrossrefMedlineGoogle Scholar5. Lechner MG, Vyas CM, Hamnvik OR, Alexander EK, Larsen PR, Choueiri TK, et al. Hypothyroidism during tyrosine kinase inhibitor therapy is associated with longer survival in patients with advanced nonthyroidal cancers. Thyroid. 2018;28:445-53. [PMID: 29652597] doi:10.1089/thy.2017.0587 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Texas Tech University Health Sciences Center, Lubbock, Texas (A.B., S.J., M.G., A.N.P.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L18-0430. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTreatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase François-Xavier Mahon , Carla Boquimpani , Dong-Wook Kim , Noam Benyamini , Nelma Cristina D. Clementino , Vasily Shuvaev , Sikander Ailawadhi , Jeffrey Howard Lipton , Anna G. Turkina , Raquel De Paz , Beatriz Moiraghi , Franck E. Nicolini , Jolanta Dengler , Tomasz Sacha , Naoto Takahashi , Rafik Fellague-Chebra , Sandip Acharya , Stephane Wong , Yu Jin , and Timothy P. Hughes Treatment-Free Remission After Second-Line Nilotinib Treatment François-Xavier Mahon and Timothy P. Hughes Metrics Cited byProtective effect of a new heterocyclic compound on acute tracheobronchitis via reducing IL-6 and TNF-α content and PKA-NF-κB pathway activation 2 October 2018Volume 169, Issue 7Page: 509-510KeywordsAdverse reactionsChronic myelocytic leukemiaChronic myeloid leukemiaDisclosureHypothyroidismPatientsSerious adverse eventsThyroidTyrosine kinase inhibitors ePublished: 2 October 2018 Issue Published: 2 October 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...